Allergy Immunotherapy Market Size, Share & Forecast to 2032

The Allergy Immunotherapy Market is projected to reach USD 2.24 Billion in 2026. It is expected to continue growing at a CAGR of 10.36%, reaching USD 4.07 Billion by 2032.

Allergy immunotherapy is the only disease-modifying treatment class designed to induce immune tolerance to clinically relevant allergens rather than only suppress symptoms. In practice, subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT) are used for allergic rhinitis, allergic conjunctivitis, selected allergic asthma, venom hypersensitivity, and specific inhalant allergens such as grass pollen, ragweed, birch, and house dust mite.

The allergy immunotherapy market is shaped by the persistent global burden of allergic rhinitis and asthma, guideline-backed use in appropriately selected patients, and rising demand for long-term control when antihistamines, intranasal corticosteroids, and allergen-avoidance strategies are insufficient. Regulatory agencies, including the U.S. FDA and European medicines authorities, continue to emphasize standardized allergen extracts, evidence-based labeling, pharmacovigilance, and patient safety, while professional societies such as EAACI, AAAAI, ACAAI, and ARIA reinforce the role of allergen immunotherapy in integrated allergy care.

Commercial momentum is strongest where accurate diagnosis, specialist referral, reimbursement, and adherence support converge. Stakeholders that combine clinically validated products, reliable allergen extract supply, digital adherence tools, and real-world evidence generation are best positioned in the allergy immunotherapy market.

Transformative Shifts in the Allergy Immunotherapy Landscape

The allergy immunotherapy landscape is moving from clinic-administered, extract-centered models toward more standardized, patient-centric, evidence-driven care. SLIT tablets have expanded the treatment conversation by offering convenient, at-home maintenance dosing after supervised initiation, while SCIT remains widely used because clinicians can tailor extract combinations to sensitization profiles under controlled protocols.

Several structural shifts are redefining competition. Climate-related pollen season lengthening, urban air pollution exposure, indoor allergen exposure, and higher awareness of allergic rhinitis and asthma comorbidity are increasing demand for durable interventions. At the same time, regulators and payers are scrutinizing clinical endpoints, product consistency, safety monitoring, and long-term value, pushing manufacturers toward stronger trial design and post-market evidence.

The market is also shifting toward precision allergy management. Component-resolved diagnostics, molecular allergy testing, and better patient phenotyping help differentiate clinically relevant sensitization from cross-reactivity, improving candidate selection and reducing avoidable treatment failure. This supports a more outcome-oriented allergy immunotherapy market with higher emphasis on adherence, persistence, and measurable quality-of-life gains.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming a cumulative force across allergy immunotherapy research, commercialization, and patient management. In discovery and development, AI can support allergen sequence analysis, epitope mapping, formulation optimization, and safety signal review, accelerating the identification of candidates with improved efficacy and tolerability profiles.

In clinical operations, AI-enabled analytics can help improve trial recruitment by matching sensitization patterns, symptom history, geography, pollen exposure, and comorbid asthma status to protocol requirements. In care delivery, predictive models can flag patients at risk of non-adherence, missed injections, adverse reactions, or symptom escalation, enabling more timely clinician outreach and improved treatment persistence.

The most credible AI impact will come from transparent, validated tools integrated with electronic health records, pharmacy data, diagnostic results, wearable data where available, and environmental exposure datasets such as pollen and air-quality monitoring. Industry leaders should treat AI as an evidence amplifier rather than a substitute for controlled trials, physician judgment, and regulatory-grade pharmacovigilance.

Key Regional Insights: Asia-Pacific, North America, Europe, Latin America, Middle East & Africa

In Asia-Pacific, allergy immunotherapy development is supported by large populations, rising urbanization, increasing recognition of allergic rhinitis and asthma, and expanding access to specialist care in China, India, Japan, South Korea, and Australia. Market maturity varies widely because reimbursement, allergen extract standardization, diagnostic coverage, and allergy specialist density differ across countries; however, demand is rising as patients seek longer-term symptom control and clinicians adopt more structured allergy testing pathways.

North America remains a highly developed allergy immunotherapy region, led by the United States and Canada, where SCIT is deeply embedded in allergy practice and FDA-approved SLIT tablets provide standardized options for selected allergens. Latin America, including Brazil and Mexico, presents a growing but uneven opportunity as private care access, diagnostic capacity, physician training, and availability of standardized extracts influence uptake across urban and specialty-care settings.

Europe is a mature and clinically influential allergy immunotherapy market supported by strong guideline adoption, national reimbursement structures, pharmacovigilance systems, and well-established regulatory expectations for product quality and evidence. The Middle East, particularly GCC countries, is gaining attention as allergic disease is influenced by dust exposure, indoor allergens, climate conditions, and air quality, while Africa remains an emerging opportunity where access to allergy diagnostics, specialist infrastructure, affordability, and consistent product supply are primary constraints.

Key Group Insights: ASEAN, GCC, EU, BRICS, G7, and NATO

ASEAN markets are increasingly relevant as urban growth, air pollution exposure, and middle-class healthcare spending raise demand for allergy diagnosis and treatment, although reimbursement, standardized product availability, and specialist access remain inconsistent across member countries. The GCC is positioned for premium allergy care expansion because of healthcare investment, private-sector capacity, medical tourism activity, and environmental exposure to dust, molds, and indoor allergens.

The European Union provides one of the most structured environments for allergy immunotherapy, with harmonized regulatory expectations, established pharmacovigilance, and strong clinical society influence across allergic rhinitis, allergic asthma, and venom allergy care. BRICS countries represent high-volume potential, especially China, India, Brazil, and South Africa, but require localized pricing, scalable diagnostics, cold-chain reliability where applicable, and evidence that fits diverse public and private healthcare systems.

G7 markets offer a strong combination of regulatory clarity, payer evaluation, clinical infrastructure, and innovation financing, making them central to product launches, real-world evidence programs, and long-term adherence models. NATO countries overlap substantially with North American and European developed markets, where resilient supply chains, medical preparedness, cross-border quality standards, and established pharmacovigilance support stable access to regulated allergen immunotherapy products.

Key Country Insights Across Major Allergy Immunotherapy Markets

The United States is the largest single commercial opportunity within allergy immunotherapy because of its established allergist network, extensive SCIT use, FDA-regulated SLIT tablets, and payer-driven emphasis on documented medical necessity and guideline-aligned care. Canada shows steady demand through specialist-led allergy care and public-private reimbursement pathways, while Mexico and Brazil offer expanding private-market potential as diagnostic access, urban specialty care, and physician training improve.

In Europe, the United Kingdom, Germany, France, Italy, and Spain benefit from mature allergy practice patterns, guideline awareness, and established pathways for allergic rhinitis, asthma comorbidity assessment, and venom hypersensitivity management. Germany and France are particularly important because of their long-standing clinical adoption of allergen immunotherapy and emphasis on standardized products. Russia has demand potential due to allergic disease burden but faces market-access, regulatory, and supply-chain complexity, while the broader European environment continues to prioritize standardized extracts and evidence-based use.

China and India represent major long-term opportunities due to large allergic disease populations, urban air quality challenges, increasing healthcare spending, and expanding specialty care, though affordability, diagnostic coverage, and physician training remain critical. Japan, South Korea, and Australia are more developed Asia-Pacific markets with stronger regulatory systems, higher diagnostic awareness, and clearer clinical adoption pathways, making them attractive for standardized SLIT and high-quality SCIT portfolios supported by adherence monitoring and post-market evidence.

Actionable Recommendations for Allergy Immunotherapy Leaders

Industry leaders should prioritize differentiated evidence. Products and services need clear clinical positioning by allergen, patient phenotype, safety profile, adherence pattern, and long-term outcome, supported by randomized trials, registry data, and real-world evidence.

Manufacturers should strengthen supply-chain resilience for standardized allergen extracts, invest in physician and patient education, and build digital adherence programs that reduce discontinuation across multi-year treatment courses. Partnerships with diagnostic providers can improve patient selection and help align immunotherapy initiation with clinically relevant sensitization rather than sensitization alone.

Commercial teams should localize market access strategy by reimbursement maturity. In developed markets, value messaging should focus on disease modification, reduced symptom burden, lower medication reliance, and quality-of-life improvement; in emerging markets, success depends on affordability, specialist training, scalable diagnostic pathways, and reliable availability of regulated products.

Research Methodology

This executive summary is based on a structured secondary-research methodology using publicly available and verifiable sources, including regulatory guidance, professional society guidelines, peer-reviewed clinical literature, product labels, epidemiology publications, and health-system documentation. Sources considered include agencies and organizations such as the FDA, EMA, WHO-linked allergy literature, EAACI, AAAAI, ACAAI, ARIA, and national health authorities.

The analysis emphasizes triangulation across clinical evidence, regulatory status, regional healthcare infrastructure, reimbursement context, diagnostic access, and market-access conditions. No unsupported market sizing, market share, or speculative forecasting is included; insights are framed around documented disease burden, approved treatment modalities, observed care pathways, regulatory standards, and validated industry drivers.

Qualitative assessment was applied to compare regions, country groups, and major national markets based on specialist availability, diagnostic capacity, product standardization, patient adherence requirements, payer acceptance, pharmacovigilance systems, and supply-chain reliability.

Conclusion: Outlook for Allergy Immunotherapy

The allergy immunotherapy market is entering a more disciplined phase in which clinical credibility, product standardization, adherence support, and real-world outcomes determine competitive strength. SCIT remains foundational in specialist allergy practice, while SLIT expands convenience and standardization for selected allergens.

Future advancement will depend on precise diagnosis, patient selection, sustained treatment persistence, and evidence that demonstrates durable benefits beyond symptomatic relief. Stakeholders that combine validated immunotherapy portfolios with AI-enabled analytics, regional market access expertise, reliable supply chains, and strong pharmacovigilance will be best positioned to lead the next stage of allergy care.

Additional Product Information:

Purchase of this report includes 1 year online access with quarterly updates.
This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

1. Preface

1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders

2. Research Methodology

2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations

3. Executive Summary

3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap

4. Market Overview

4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy

5. Market Insights

5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Allergy Immunotherapy Market, by Allergy Type

7.1. Allergic Asthma
7.2. Allergic Rhinitis
7.3. Atopic Dermatitis
7.4. Urticaria

8. Allergy Immunotherapy Market, by Allergen Type

8.1. Animal Dander
8.1.1. Cat Allergens
8.1.2. Dog Allergens
8.2. Dust Mites
8.3. Food Allergens
8.3.1. Egg Allergens
8.3.2. Milk Allergens
8.3.3. Peanut Allergens
8.3.4. Tree Nut Allergens
8.4. Pollen

9. Allergy Immunotherapy Market, by Immunotherapy Delivery Form

9.1. Dermal Patch
9.2. Drops
9.3. Injections
9.4. Tablets

10. Allergy Immunotherapy Market, by Technology Platform

10.1. Adjuvants
10.2. Nanotechnology-Based Platforms
10.3. Recombinant Allergens

11. Allergy Immunotherapy Market, by Treatment Type

11.1. Epicutaneous Immunotherapy
11.2. Oral Immunotherapy
11.3. Subcutaneous Immunotherapy
11.4. Sublingual Immunotherapy

12. Allergy Immunotherapy Market, by End User

12.1. Homecare Settings
12.2. Hospitals
12.3. Research & Academic Laboratories
12.4. Specialty Clinics

13. Allergy Immunotherapy Market, by Distribution Channel

13.1. Hospital Pharmacy
13.2. Online Pharmacy
13.3. Retail Pharmacy

14. Asia-Pacific Allergy Immunotherapy Market
15. North America Allergy Immunotherapy Market
16. Latin America Allergy Immunotherapy Market
17. Europe Allergy Immunotherapy Market
18. Middle East Allergy Immunotherapy Market
19. Africa Allergy Immunotherapy Market
20. ASEAN Allergy Immunotherapy Market
21. GCC Allergy Immunotherapy Market
22. European Union Allergy Immunotherapy Market
23. BRICS Allergy Immunotherapy Market
24. G7 Allergy Immunotherapy Market
25. NATO Allergy Immunotherapy Market
26. United States Allergy Immunotherapy Market
27. Canada Allergy Immunotherapy Market
28. Mexico Allergy Immunotherapy Market
29. Brazil Allergy Immunotherapy Market
30. United Kingdom Allergy Immunotherapy Market
31. Germany Allergy Immunotherapy Market
32. France Allergy Immunotherapy Market
33. Russia Allergy Immunotherapy Market
34. Italy Allergy Immunotherapy Market
35. Spain Allergy Immunotherapy Market
36. China Allergy Immunotherapy Market
37. India Allergy Immunotherapy Market
38. Japan Allergy Immunotherapy Market
39. Australia Allergy Immunotherapy Market
40. South Korea Allergy Immunotherapy Market

41. Competitive Landscape

41.1. Market Concentration Analysis, 2025
41.1.1. Concentration Ratio (CR)
41.1.2. Herfindahl Hirschman Index (HHI)
41.2. Recent Developments & Impact Analysis, 2025
41.3. Product Portfolio Analysis, 2025
41.4. Benchmarking Analysis, 2025

42. Company Profiles

42.1. Adamis Pharmaceuticals Corporation
42.2. Aimmune Therapeutics Inc.
42.3. ALK-Abelló A/S
42.4. Allergopharma GmbH & Co. KG
42.5. Allergy Therapeutics plc
42.6. Allovate LLC
42.7. Anergis SA
42.8. ASIT Biotech SA
42.9. Biomay AG
42.10. Camallergy Ltd.
42.11. Circassia Pharmaceuticals Inc.
42.12. DBV Technologies SA
42.13. Desentum Oy
42.14. HAL Allergy B.V.
42.15. HollisterStier Allergy Inc.
42.16. Inimmune Corporation
42.17. Inmunotek S.L.
42.18. Intrommune Therapeutics, Inc.
42.19. Jubilant HollisterStier LLC
42.20. LETI Pharma S.L.
42.21. Leti-allergoid
42.22. Merck KGaA
42.23. Mylan N.V.
42.24. Novartis AG
42.25. Prota Therapeutics Pty Ltd
42.26. Siolta Therapeutics, Inc.
42.27. Stallergenes Greer International AG
42.28. Thermo Fisher Scientific Inc.
42.29. Torii Pharmaceutical Co., Ltd.
42.30. WOLW Pharma Limited

List of Figures

FIGURE 1. GLOBAL ALLERGY IMMUNOTHERAPY MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL ALLERGY IMMUNOTHERAPY MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL ALLERGY IMMUNOTHERAPY MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL ALLERGY IMMUNOTHERAPY MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 6. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 7. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 9. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 11. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 13. GLOBAL ALLERGY IMMUNOTHERAPY MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
FIGURE 14. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2025 VS 2032 (%)
FIGURE 15. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2025 VS 2032 (%)
FIGURE 17. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2025 VS 2032 (%)
FIGURE 19. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025 VS 2032 (%)
FIGURE 21. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2032 (%)
FIGURE 23. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 25. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 26. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 27. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 28. ASIA-PACIFIC ALLERGY IMMUNOTHERAPY MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 29. ASIA-PACIFIC ALLERGY IMMUNOTHERAPY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 30. NORTH AMERICA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 31. NORTH AMERICA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 32. LATIN AMERICA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 33. LATIN AMERICA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 34. EUROPE ALLERGY IMMUNOTHERAPY MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 35. EUROPE ALLERGY IMMUNOTHERAPY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 36. MIDDLE EAST ALLERGY IMMUNOTHERAPY MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 37. MIDDLE EAST ALLERGY IMMUNOTHERAPY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 38. AFRICA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 39. AFRICA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 40. ASEAN ALLERGY IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 41. ASEAN ALLERGY IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 42. GCC ALLERGY IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 43. GCC ALLERGY IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 44. EUROPEAN UNION ALLERGY IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 45. EUROPEAN UNION ALLERGY IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 46. BRICS ALLERGY IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 47. BRICS ALLERGY IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 48. G7 ALLERGY IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 49. G7 ALLERGY IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 50. NATO ALLERGY IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 51. NATO ALLERGY IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 52. UNITED STATES ALLERGY IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 53. CANADA ALLERGY IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 54. MEXICO ALLERGY IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 55. BRAZIL ALLERGY IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 56. UNITED KINGDOM ALLERGY IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 57. GERMANY ALLERGY IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 58. FRANCE ALLERGY IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 59. RUSSIA ALLERGY IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 60. ITALY ALLERGY IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 61. SPAIN ALLERGY IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 62. CHINA ALLERGY IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 63. INDIA ALLERGY IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 64. JAPAN ALLERGY IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 65. AUSTRALIA ALLERGY IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 66. SOUTH KOREA ALLERGY IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)

List of Tables

TABLE 1. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SHARE, BY KEY PLAYER, 2025
TABLE 7. GLOBAL ALLERGY IMMUNOTHERAPY MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
TABLE 8. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL ALLERGIC ASTHMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL ALLERGIC ASTHMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL ALLERGIC ASTHMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL ALLERGIC RHINITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL ALLERGIC RHINITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL ALLERGIC RHINITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL URTICARIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL URTICARIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL URTICARIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL ANIMAL DANDER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL ANIMAL DANDER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL ANIMAL DANDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL CAT ALLERGENS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL CAT ALLERGENS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL CAT ALLERGENS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL DOG ALLERGENS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL DOG ALLERGENS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL DOG ALLERGENS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL DUST MITES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL DUST MITES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL DUST MITES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL FOOD ALLERGENS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL FOOD ALLERGENS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL FOOD ALLERGENS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL EGG ALLERGENS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL EGG ALLERGENS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL EGG ALLERGENS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL MILK ALLERGENS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL MILK ALLERGENS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL MILK ALLERGENS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL PEANUT ALLERGENS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL PEANUT ALLERGENS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL PEANUT ALLERGENS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL TREE NUT ALLERGENS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL TREE NUT ALLERGENS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL TREE NUT ALLERGENS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL POLLEN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL POLLEN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL POLLEN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL DERMAL PATCH MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL DERMAL PATCH MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL DERMAL PATCH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL DROPS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL DROPS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL DROPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL INJECTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL INJECTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL INJECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL TABLETS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL TABLETS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL ADJUVANTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL ADJUVANTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL ADJUVANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL NANOTECHNOLOGY-BASED PLATFORMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL NANOTECHNOLOGY-BASED PLATFORMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL NANOTECHNOLOGY-BASED PLATFORMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL RECOMBINANT ALLERGENS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL RECOMBINANT ALLERGENS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL RECOMBINANT ALLERGENS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL EPICUTANEOUS IMMUNOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL EPICUTANEOUS IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL EPICUTANEOUS IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL ORAL IMMUNOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL ORAL IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL ORAL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL SUBCUTANEOUS IMMUNOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL SUBCUTANEOUS IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL SUBCUTANEOUS IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL SUBLINGUAL IMMUNOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL SUBLINGUAL IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL SUBLINGUAL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL RESEARCH & ACADEMIC LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL RESEARCH & ACADEMIC LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL RESEARCH & ACADEMIC LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 99. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 100. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 101. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 102. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 103. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 104. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 105. GLOBAL ONLINE PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 106. GLOBAL ONLINE PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 107. GLOBAL ONLINE PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 108. GLOBAL RETAIL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 109. GLOBAL RETAIL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 110. GLOBAL RETAIL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 111. ASIA-PACIFIC ALLERGY IMMUNOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 112. ASIA-PACIFIC ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2018-2032 (USD MILLION)
TABLE 113. ASIA-PACIFIC ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2018-2032 (USD MILLION)
TABLE 114. ASIA-PACIFIC ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ANIMAL DANDER, 2018-2032 (USD MILLION)
TABLE 115. ASIA-PACIFIC ALLERGY IMMUNOTHERAPY MARKET SIZE, BY FOOD ALLERGENS, 2018-2032 (USD MILLION)
TABLE 116. ASIA-PACIFIC ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2018-2032 (USD MILLION)
TABLE 117. ASIA-PACIFIC ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
TABLE 118. ASIA-PACIFIC ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 119. ASIA-PACIFIC ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 120. ASIA-PACIFIC ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 121. NORTH AMERICA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 122. NORTH AMERICA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2018-2032 (USD MILLION)
TABLE 123. NORTH AMERICA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2018-2032 (USD MILLION)
TABLE 124. NORTH AMERICA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ANIMAL DANDER, 2018-2032 (USD MILLION)
TABLE 125. NORTH AMERICA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY FOOD ALLERGENS, 2018-2032 (USD MILLION)
TABLE 126. NORTH AMERICA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2018-2032 (USD MILLION)
TABLE 127. NORTH AMERICA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
TABLE 128. NORTH AMERICA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 129. NORTH AMERICA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 130. NORTH AMERICA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 131. LATIN AMERICA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 132. LATIN AMERICA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2018-2032 (USD MILLION)
TABLE 133. LATIN AMERICA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2018-2032 (USD MILLION)
TABLE 134. LATIN AMERICA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ANIMAL DANDER, 2018-2032 (USD MILLION)
TABLE 135. LATIN AMERICA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY FOOD ALLERGENS, 2018-2032 (USD MILLION)
TABLE 136. LATIN AMERICA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2018-2032 (USD MILLION)
TABLE 137. LATIN AMERICA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
TABLE 138. LATIN AMERICA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 139. LATIN AMERICA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 140. LATIN AMERICA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 141. EUROPE ALLERGY IMMUNOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 142. EUROPE ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2018-2032 (USD MILLION)
TABLE 143. EUROPE ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2018-2032 (USD MILLION)
TABLE 144. EUROPE ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ANIMAL DANDER, 2018-2032 (USD MILLION)
TABLE 145. EUROPE ALLERGY IMMUNOTHERAPY MARKET SIZE, BY FOOD ALLERGENS, 2018-2032 (USD MILLION)
TABLE 146. EUROPE ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2018-2032 (USD MILLION)
TABLE 147. EUROPE ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
TABLE 148. EUROPE ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 149. EUROPE ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 150. EUROPE ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 151. MIDDLE EAST ALLERGY IMMUNOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 152. MIDDLE EAST ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2018-2032 (USD MILLION)
TABLE 153. MIDDLE EAST ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2018-2032 (USD MILLION)
TABLE 154. MIDDLE EAST ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ANIMAL DANDER, 2018-2032 (USD MILLION)
TABLE 155. MIDDLE EAST ALLERGY IMMUNOTHERAPY MARKET SIZE, BY FOOD ALLERGENS, 2018-2032 (USD MILLION)
TABLE 156. MIDDLE EAST ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2018-2032 (USD MILLION)
TABLE 157. MIDDLE EAST ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
TABLE 158. MIDDLE EAST ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 159. MIDDLE EAST ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 160. MIDDLE EAST ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 161. AFRICA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 162. AFRICA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2018-2032 (USD MILLION)
TABLE 163. AFRICA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2018-2032 (USD MILLION)
TABLE 164. AFRICA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ANIMAL DANDER, 2018-2032 (USD MILLION)
TABLE 165. AFRICA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY FOOD ALLERGENS, 2018-2032 (USD MILLION)
TABLE 166. AFRICA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2018-2032 (USD MILLION)
TABLE 167. AFRICA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
TABLE 168. AFRICA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 169. AFRICA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 170. AFRICA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 171. ASEAN ALLERGY IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 172. ASEAN ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2018-2032 (USD MILLION)
TABLE 173. ASEAN ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2018-2032 (USD MILLION)
TABLE 174. ASEAN ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ANIMAL DANDER, 2018-2032 (USD MILLION)
TABLE 175. ASEAN ALLERGY IMMUNOTHERAPY MARKET SIZE, BY FOOD ALLERGENS, 2018-2032 (USD MILLION)
TABLE 176. ASEAN ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2018-2032 (USD MILLION)
TABLE 177. ASEAN ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
TABLE 178. ASEAN ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 179. ASEAN ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 180. ASEAN ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 181. GCC ALLERGY IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 182. GCC ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2018-2032 (USD MILLION)
TABLE 183. GCC ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2018-2032 (USD MILLION)
TABLE 184. GCC ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ANIMAL DANDER, 2018-2032 (USD MILLION)
TABLE 185. GCC ALLERGY IMMUNOTHERAPY MARKET SIZE, BY FOOD ALLERGENS, 2018-2032 (USD MILLION)
TABLE 186. GCC ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2018-2032 (USD MILLION)
TABLE 187. GCC ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
TABLE 188. GCC ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 189. GCC ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 190. GCC ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 191. EUROPEAN UNION ALLERGY IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 192. EUROPEAN UNION ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2018-2032 (USD MILLION)
TABLE 193. EUROPEAN UNION ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2018-2032 (USD MILLION)
TABLE 194. EUROPEAN UNION ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ANIMAL DANDER, 2018-2032 (USD MILLION)
TABLE 195. EUROPEAN UNION ALLERGY IMMUNOTHERAPY MARKET SIZE, BY FOOD ALLERGENS, 2018-2032 (USD MILLION)
TABLE 196. EUROPEAN UNION ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2018-2032 (USD MILLION)
TABLE 197. EUROPEAN UNION ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
TABLE 198. EUROPEAN UNION ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 199. EUROPEAN UNION ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 200. EUROPEAN UNION ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 201. BRICS ALLERGY IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 202. BRICS ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2018-2032 (USD MILLION)
TABLE 203. BRICS ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2018-2032 (USD MILLION)
TABLE 204. BRICS ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ANIMAL DANDER, 2018-2032 (USD MILLION)
TABLE 205. BRICS ALLERGY IMMUNOTHERAPY MARKET SIZE, BY FOOD ALLERGENS, 2018-2032 (USD MILLION)
TABLE 206. BRICS ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2018-2032 (USD MILLION)
TABLE 207. BRICS ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
TABLE 208. BRICS ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 209. BRICS ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 210. BRICS ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 211. G7 ALLERGY IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 212. G7 ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2018-2032 (USD MILLION)
TABLE 213. G7 ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2018-2032 (USD MILLION)
TABLE 214. G7 ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ANIMAL DANDER, 2018-2032 (USD MILLION)
TABLE 215. G7 ALLERGY IMMUNOTHERAPY MARKET SIZE, BY FOOD ALLERGENS, 2018-2032 (USD MILLION)
TABLE 216. G7 ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2018-2032 (USD MILLION)
TABLE 217. G7 ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
TABLE 218. G7 ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 219. G7 ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 220. G7 ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 221. NATO ALLERGY IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 222. NATO ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2018-2032 (USD MILLION)
TABLE 223. NATO ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2018-2032 (USD MILLION)
TABLE 224. NATO ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ANIMAL DANDER, 2018-2032 (USD MILLION)
TABLE 225. NATO ALLERGY IMMUNOTHERAPY MARKET SIZE, BY FOOD ALLERGENS, 2018-2032 (USD MILLION)
TABLE 226. NATO ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2018-2032 (USD MILLION)
TABLE 227. NATO ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
TABLE 228. NATO ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 229. NATO ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 230. NATO ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 231. UNITED STATES ALLERGY IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 232. UNITED STATES ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2018-2032 (USD MILLION)
TABLE 233. UNITED STATES ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2018-2032 (USD MILLION)
TABLE 234. UNITED STATES ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ANIMAL DANDER, 2018-2032 (USD MILLION)
TABLE 235. UNITED STATES ALLERGY IMMUNOTHERAPY MARKET SIZE, BY FOOD ALLERGENS, 2018-2032 (USD MILLION)
TABLE 236. UNITED STATES ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2018-2032 (USD MILLION)
TABLE 237. UNITED STATES ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
TABLE 238. UNITED STATES ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 239. UNITED STATES ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 240. UNITED STATES ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 241. CANADA ALLERGY IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 242. CANADA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2018-2032 (USD MILLION)
TABLE 243. CANADA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2018-2032 (USD MILLION)
TABLE 244. CANADA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ANIMAL DANDER, 2018-2032 (USD MILLION)
TABLE 245. CANADA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY FOOD ALLERGENS, 2018-2032 (USD MILLION)
TABLE 246. CANADA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2018-2032 (USD MILLION)
TABLE 247. CANADA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
TABLE 248. CANADA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 249. CANADA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 250. CANADA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 251. MEXICO ALLERGY IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 252. MEXICO ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2018-2032 (USD MILLION)
TABLE 253. MEXICO ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2018-2032 (USD MILLION)
TABLE 254. MEXICO ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ANIMAL DANDER, 2018-2032 (USD MILLION)
TABLE 255. MEXICO ALLERGY IMMUNOTHERAPY MARKET SIZE, BY FOOD ALLERGENS, 2018-2032 (USD MILLION)
TABLE 256. MEXICO ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2018-2032 (USD MILLION)
TABLE 257. MEXICO ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
TABLE 258. MEXICO ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 259. MEXICO ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 260. MEXICO ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 261. BRAZIL ALLERGY IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 262. BRAZIL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2018-2032 (USD MILLION)
TABLE 263. BRAZIL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2018-2032 (USD MILLION)
TABLE 264. BRAZIL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ANIMAL DANDER, 2018-2032 (USD MILLION)
TABLE 265. BRAZIL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY FOOD ALLERGENS, 2018-2032 (USD MILLION)
TABLE 266. BRAZIL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2018-2032 (USD MILLION)
TABLE 267. BRAZIL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
TABLE 268. BRAZIL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 269. BRAZIL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 270. BRAZIL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 271. UNITED KINGDOM ALLERGY IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 272. UNITED KINGDOM ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2018-2032 (USD MILLION)
TABLE 273. UNITED KINGDOM ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2018-2032 (USD MILLION)
TABLE 274. UNITED KINGDOM ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ANIMAL DANDER, 2018-2032 (USD MILLION)
TABLE 275. UNITED KINGDOM ALLERGY IMMUNOTHERAPY MARKET SIZE, BY FOOD ALLERGENS, 2018-2032 (USD MILLION)
TABLE 276. UNITED KINGDOM ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2018-2032 (USD MILLION)
TABLE 277. UNITED KINGDOM ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
TABLE 278. UNITED KINGDOM ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 279. UNITED KINGDOM ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 280. UNITED KINGDOM ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 281. GERMANY ALLERGY IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 282. GERMANY ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2018-2032 (USD MILLION)
TABLE 283. GERMANY ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2018-2032 (USD MILLION)
TABLE 284. GERMANY ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ANIMAL DANDER, 2018-2032 (USD MILLION)
TABLE 285. GERMANY ALLERGY IMMUNOTHERAPY MARKET SIZE, BY FOOD ALLERGENS, 2018-2032 (USD MILLION)
TABLE 286. GERMANY ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2018-2032 (USD MILLION)
TABLE 287. GERMANY ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
TABLE 288. GERMANY ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 289. GERMANY ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 290. GERMANY ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 291. FRANCE ALLERGY IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 292. FRANCE ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2018-2032 (USD MILLION)
TABLE 293. FRANCE ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2018-2032 (USD MILLION)
TABLE 294. FRANCE ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ANIMAL DANDER, 2018-2032 (USD MILLION)
TABLE 295. FRANCE ALLERGY IMMUNOTHERAPY MARKET SIZE, BY FOOD ALLERGENS, 2018-2032 (USD MILLION)
TABLE 296. FRANCE ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2018-2032 (USD MILLION)
TABLE 297. FRANCE ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
TABLE 298. FRANCE ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 299. FRANCE ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 300. FRANCE ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 301. RUSSIA ALLERGY IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 302. RUSSIA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2018-2032 (USD MILLION)
TABLE 303. RUSSIA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2018-2032 (USD MILLION)
TABLE 304. RUSSIA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ANIMAL DANDER, 2018-2032 (USD MILLION)
TABLE 305. RUSSIA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY FOOD ALLERGENS, 2018-2032 (USD MILLION)
TABLE 306. RUSSIA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2018-2032 (USD MILLION)
TABLE 307. RUSSIA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
TABLE 308. RUSSIA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 309. RUSSIA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 310. RUSSIA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 311. ITALY ALLERGY IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 312. ITALY ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2018-2032 (USD MILLION)
TABLE 313. ITALY ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2018-2032 (USD MILLION)
TABLE 314. ITALY ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ANIMAL DANDER, 2018-2032 (USD MILLION)
TABLE 315. ITALY ALLERGY IMMUNOTHERAPY MARKET SIZE, BY FOOD ALLERGENS, 2018-2032 (USD MILLION)
TABLE 316. ITALY ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2018-2032 (USD MILLION)
TABLE 317. ITALY ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
TABLE 318. ITALY ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 319. ITALY ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 320. ITALY ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 321. SPAIN ALLERGY IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 322. SPAIN ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2018-2032 (USD MILLION)
TABLE 323. SPAIN ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2018-2032 (USD MILLION)
TABLE 324. SPAIN ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ANIMAL DANDER, 2018-2032 (USD MILLION)
TABLE 325. SPAIN ALLERGY IMMUNOTHERAPY MARKET SIZE, BY FOOD ALLERGENS, 2018-2032 (USD MILLION)
TABLE 326. SPAIN ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2018-2032 (USD MILLION)
TABLE 327. SPAIN ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
TABLE 328. SPAIN ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 329. SPAIN ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 330. SPAIN ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 331. CHINA ALLERGY IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 332. CHINA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2018-2032 (USD MILLION)
TABLE 333. CHINA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2018-2032 (USD MILLION)
TABLE 334. CHINA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ANIMAL DANDER, 2018-2032 (USD MILLION)
TABLE 335. CHINA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY FOOD ALLERGENS, 2018-2032 (USD MILLION)
TABLE 336. CHINA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2018-2032 (USD MILLION)
TABLE 337. CHINA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
TABLE 338. CHINA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 339. CHINA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 340. CHINA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 341. INDIA ALLERGY IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 342. INDIA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2018-2032 (USD MILLION)
TABLE 343. INDIA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2018-2032 (USD MILLION)
TABLE 344. INDIA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ANIMAL DANDER, 2018-2032 (USD MILLION)
TABLE 345. INDIA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY FOOD ALLERGENS, 2018-2032 (USD MILLION)
TABLE 346. INDIA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2018-2032 (USD MILLION)
TABLE 347. INDIA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
TABLE 348. INDIA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 349. INDIA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 350. INDIA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 351. JAPAN ALLERGY IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 352. JAPAN ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2018-2032 (USD MILLION)
TABLE 353. JAPAN ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2018-2032 (USD MILLION)
TABLE 354. JAPAN ALLERGY IMMUNOT

Companies Mentioned

The companies featured in this Allergy Immunotherapy market report include:

Adamis Pharmaceuticals Corporation
Aimmune Therapeutics Inc.
ALK‑Abelló A/S
Allergopharma GmbH & Co. KG
Allergy Therapeutics plc
Allovate LLC
Anergis SA
ASIT Biotech SA
Biomay AG
Camallergy Ltd.
Circassia Pharmaceuticals Inc.
DBV Technologies SA
Desentum Oy
HAL Allergy B.V.
HollisterStier Allergy Inc.
Inimmune Corporation
Inmunotek S.L.
Intrommune Therapeutics, Inc.
Jubilant HollisterStier LLC
LETI Pharma S.L.
Leti‑allergoid
Merck KGaA
Mylan N.V.
Novartis AG
Prota Therapeutics Pty Ltd
Siolta Therapeutics, Inc.
Stallergenes Greer International AG
Thermo Fisher Scientific Inc.
Torii Pharmaceutical Co., Ltd.
WOLW Pharma Limited

Table Information

Report Attribute	Details
No. of Pages	186
Published	June 2026
Forecast Period	2026 - 2032
Estimated Market Value ( USD ) in 2026	$ 2.24 Billion
Forecasted Market Value ( USD ) by 2032	$ 4.07 Billion
Compound Annual Growth Rate	10.3%
Regions Covered	Global
No. of Companies Mentioned	31

License	Format	Properties	Price
1 - 5 USER LICENSE PDF, Excel and Online Access		This is a 1-5 user license, allowing up to five users have access to the product.	€3218EUR$3,545USD£2,772GBP €3576EUR$3,939USD£3,080GBP
ENTERPRISE LICENSE PDF, Excel and Online Access		This is an enterprise license, allowing all employees within your organization access to the product.	€4868EUR$5,363USD£4,194GBP €5409EUR$5,959USD£4,660GBP

Allergy Immunotherapy Market by Allergy Type, Allergen Type, Immunotherapy Delivery Form, Technology Platform, Treatment Type, End User, Distribution Channel - Global Forecast 2026-2032

Transformative Shifts in the Allergy Immunotherapy Landscape

Cumulative Impact of Artificial Intelligence

Key Regional Insights: Asia-Pacific, North America, Europe, Latin America, Middle East & Africa

Key Group Insights: ASEAN, GCC, EU, BRICS, G7, and NATO

Key Country Insights Across Major Allergy Immunotherapy Markets

Actionable Recommendations for Allergy Immunotherapy Leaders

Research Methodology

Conclusion: Outlook for Allergy Immunotherapy

Table of Contents

Companies Mentioned

Table Information

Transformative Shifts in the Allergy Immunotherapy Landscape

Cumulative Impact of Artificial Intelligence

Key Regional Insights: Asia-Pacific, North America, Europe, Latin America, Middle East & Africa

Key Group Insights: ASEAN, GCC, EU, BRICS, G7, and NATO

Key Country Insights Across Major Allergy Immunotherapy Markets

Actionable Recommendations for Allergy Immunotherapy Leaders

Research Methodology

Conclusion: Outlook for Allergy Immunotherapy

Table of Contents

Companies Mentioned

Table Information

Related Topics

Related Reports

Allergy Vaccine Market by Vaccine Type, Route of Administration, Allergens Targeted, Technology, Patient Age Group, End User, Distribution Channel - Global Forecast 2026-2032

Allergy Treatment Market - Global Forecast 2026-2032

Allergy Shots Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

Allergy Immunotherapies Market Size, Share, Trends and Forecast by Treatment Type, Allergy Type, Distribution Channel, and Region, 2026-2034

Allergy Immunotherapy - Global Strategic Business Report

About the Allergy Immunotherapy Market